CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 71 enrolled
Drug / intervention
Erythropoietin-Beta +1 moredrug
Likely dose
Erythropoietin-Beta 300 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00654992
NCT00654992Phase 3Completed
CompareCT.gov

Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial

Seoul National University Bundang Hospital·interventional·Posted Apr 9, 2008·Updated Jun 16, 2009

In Brief

A Phase 3 clinical trial evaluating Erythropoietin-Beta and Normal Saline for Kidney Failure, Acute. Completed, enrolled 71 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Failure, Acute
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 9, 2008
Enrollment StartSep 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.2 years ago

Interventions

Erythropoietin-Betadrug

300 IU/kg of EPO or saline intravenously before surgery

Normal Salinedrug

300 IU/kg of normal saline intravenously before surgery